ENT Focused Lyra Therapeutics Banks $29.5 Million Series B Round

[cafead]

via

• LYR-210 has the potential to be the first approved drug product for CRS
• The product can deliver relief for up to six months
• In the United States, chronic rhinosinusitis has an estimated prevalence of 1% to 5%

article source